
Please try another search
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Name | Age | Since | Title |
---|---|---|---|
Sharon Malka | 50 | 2007 | Director |
Assaf Segal | - | 2017 | Director |
Nissim Mashiach | 61 | 2017 | Independent Director |
Vickie R. Driver | 68 | 2017 | Independent Director |
David Fox | - | 2020 | Independent Director |
Nachum Shamir | 68 | 2022 | Chairman of the Board |
Sharon Kochan | 54 | 2017 | Independent Director |
Stephen T. Wills | 65 | 2017 | Executive Director |
Eric Shem-Tov | - | 2022 | Member of Strategic Advisory Board |
John C. Lantis | - | 2022 | Member of Strategic Advisory Board |
Samuel J. Moed | 59 | 2020 | Member of Strategic Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review